Clinical trial NCT06838676: ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Official title: A Phase II Trial of ACT001 in Children and Adolescents with Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Diffuse Intrinsic Pontine Gliomas (DIPG)
Progressive DIPG
Refractory DIPG
Recurrent DIPG
H3K27-altered High Grade Glioma
Keywords: High Grade Glioma
Diffuse Intrinsic Pontine Glioma
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
Collaborators: name: Accendatech USA Inc.
First posted: 2025-02-21
Enrollment: 60
Sex: ALL
Minimum age (years): 12
Maximum age (years): 39
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: ACT001
Primary purpose: TREATMENT

Brief summary: This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.

Detailed description: Patients will be enrolled on either Cohort A for newly diagnosed DIPG or on Cohort B for those with progressive / refractory DIPG or progressive / recurrent / refractory H3K27-altered HGG. Each cohort will receive ACT001 at 875 mg/m2 orally BID for 28 days (1 cycle of treatment), up to a maximum dose of 1700 mg BID. If patients are experiencing clinical benefit from study therapy, they will continue to receive ACT001 in repeat 28-day cycles for up to 26 cycles (approximately 2 years) or until disease progression, whichever occurs first. Continuation of treatment beyond 26 cycles may be considered if patients are receiving clinical benefit from the study, at the discretion of the sponsor and treating physician.

Eligibility criteria: Inclusion Criteria:

1. Patients must be \> 12 months and \< 39 years of age at the time of study enrollment.
2. Diagnosis:

   * Cohort A: Newly Diagnosed DIPG

     * Patients with newly-diagnosed DIPG with typical MRI findings (tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons) with or without biopsy and have completed radiation therapy (RT) within 28 to 35 calendar day prior to start of therapy.
     * Patients must have started RT within 31 calendar days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery, whichever is later.

       * If a biopsy was performed, the date of surgical biopsy will be considered the date of definitive diagnostic surgery; if a patient underwent two upfront surgeries \[e.g., biopsy then debulking\], this is the date of the second surgery)
     * Patients must have received RT, but no other anti-cancer therapy other than surgery, and/or steroids prior to enrollment.
   * Cohort B: progressive/refractory/recurrent DIPG or H3K27-altered HGG

     * Patients with DIPG (no biopsy required) or pathologically-confirmed (at diagnosis or recurrence) extra-pontine H3K27-altered HGG who have progressive, refractory or recurrent disease following frontline treatment that included at least focal RT. Patients with refractory disease must have completed RT \>6 months prior to study enrollment.
     * Patients with progressive disease only at the primary site(s) must have completed RT more than 3 months prior to enrollment.
     * Patients with progressive disease only at the primary site(s) who completed radiation therapy 3 to 6 months prior to enrollment must have had at least one follow up MRI to confirm progression (rather than pseudo- progression)
     * Patients with progressive disease due to the development a new metastatic site are eligible as long as eligibility criteria 3 (disease status) and 5 (prior RT) are met.
     * Patients with metastatic disease are eligible.
3. Disease Status

   * Cohort A: patients may have any disease status but must have completed initial radiation therapy (RT) before enrollment.
   * Cohort B: Patients must have measurable disease assessable by MRI imaging. Patients may have metastatic disease. Lesions irradiated within the last 6 months are not considered measurable unless they show definitive progression following RT.
4. Performance Level: Karnofsky Performance Scale score ≥ 50% for patients \> 16 years of age and Lansky Performance Scale score \> 50% for patients ≤ 16 years of age (applies to all patients) Note: Patients who are unable to walk because of paralysis, but who are capable of using a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
5. Prior anti-cancer therapy:

   * For Cohort A ONLY:
   * Patients must not have received any prior therapy other than surgery, radiation (focal to disease) and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy).
   * Patients must enroll and start treatment on study between 28 and 35 calendar days post-completion of RT.
   * Patients must have started RT within 31 calendar days of initial diagnosis (defined as the date of diagnostic biopsy or resection; if a patient underwent two upfront surgeries \[e.g., biopsy then resection or debulking\], this is the date of the second surgery).
   * Radiotherapy must have been administered at standard dose of 54 Gy for DIPG patients. Any variances in the radiotherapy dose within 10% of the standard doses outlined above will be discussed with the Study Chair (or their delegate) to confirm eligibility prior to study enrollment.
   * For Cohort B ONLY: Patients must have fully recovered from adverse events due to prior treatment with investigational or conventional agents must have recovered to a severity of Grade 0 or Grade 1 (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 or higher), with the exception of alopecia.

   Notes to the above for Cohort B: Patients with chronic Grade 2 toxicities may be eligible per discretion of the Investigator and Sponsor (e.g., Grade 2 chemotherapy-induced neuropathy). Grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible - defined as having been present and stable for \> 6 months (such as ifosfamide-related proteinuria) may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the Investigator and Sponsor.)

   The wash out period between the prior anti-cancer chemotherapy, and first dose of ACT001 (cycle 1 day 1) must be:
   1. Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
   2. Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.
   3. Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.
   4. Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
   5. Monoclonal antibodies: \> 21 days must have elapsed from the infusion of last dose of antibody and toxicity related to antibody therapy must be recovered to Grade ≤ 1
   6. Radiation therapy:

      * For Cohort B, patients with refractory disease must have received their last fraction of frontline craniospinal or focal RT \> 6 months prior to study enrollment. Patients that have received re-irradiation for progression must have received their last fraction of focal radiation \>6 weeks or craniospinal radiation \>6 weeks prior to study enrollment.
   7. Stem Cell Transplant: Patients must be ≥ 3 months since autologous stem cell transplant. Patients who received allogenic stem cell transplant or solid organ transplant are not eligible for study
6. Organ Function Requirements (applies to all patients)

   1. Adequate bone marrow function defined as:

      * Peripheral absolute neutrophil count (ANC) \> 1000/mm³
      * Platelet count \> 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
   2. Adequate renal function defined as:

      * Creatinine clearance or radioisotope GFR \> 70 mL/min/1.73 m² or
      * A serum creatinine based on age/gender as follows (Schwartz et al. J. Peds, 106:522, 1985): Age Maximum Serum Creatinine (mg/dL) Male Female 2 to \< 6 years 0.8 0.8 6 to \< 10 years 1.0 1.0 10 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4 ≥ 16 years 1.7 1.4
   3. Adequate liver function defined as:

      * total bilirubin within normal institutional limits
      * AST (serum glutamic-oxaloacetic transaminase \[SGOT\]) / ALT (serum glutamic-oxaloacetic transaminase \[SGPT\]) ≤ 2.5 × institutional upper limit of normal
      * Serum albumin ≥ 2 g/dL
   4. Adequate cardiac function defined as:

      * Ejection fraction of ≥ 50% by echocardiogram
      * QTc ≤ 480 msec (by Bazett formula)
   5. For Cohort B: Adequate neurologic function defined as:

      * Patients with seizure disorders may be enrolled if seizures are well- controlled. Well controlled is defined by no increase in seizure frequency in the 7 days prior to enrollment.
      * Patients with neurological deficits should have deficits that are stable for at least the 7 days prior to enrollment.
7. Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
8. Life expectancy of ≥ 3 months.
9. Absence of other clinically significant concomitant active medical disorder, based on the investigator's judgement.

Exclusion Criteria:

A patient who meets any of the following exclusion criteria will not be eligible in the study (Applies to both cohorts except where noted below):

1. Cohort A only: Patients with metastatic disease.
2. Concomitant medications:

   * Corticosteroids:

     * Cohort A - Patients receiving corticosteroids are eligible regardless of dosing
     * Cohort B - Patients receiving corticosteroids who have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are eligible
   * Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible (Refer study inclusion criteria relating to anti-cancer therapies)

     * Cohort A - Patients that have received any anti-cancer treatment other than RT are not eligible.
   * Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.
   * Anticonvulsants should be used as clinically indicated. The use of enzyme inducing anticonvulsants is not permitted
   * LHRH agonist / antagonists are not permitted
   * High Dose Biotin (B7) supplements are not permitted
3. Concomitant medications used with caution: selective serotonin reuptake inhibitor (SSRI) such as Lexapro, Fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), and escitalopram should be used with caution.
4. Infection: Patients who currently have an uncontrolled infection (in the opinion of the PI) are not eligible.
5. Patients who have received a prior solid organ transplantation are not eligible.
6. Pregnant or breast-feeding women will not be entered on this study due to unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are postmenarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
7. Patients of childbearing or child fathering potential must agree to use adequate contraceptive methods (hormonal or barrier method of birth control; abstinence) while being treated on this study and for 3 months after completing therapy. Note: The definition of effective contraception will be based on the judgement of the principal investigator or a designated associate.
8. Patients who are in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
9. Patients who have previously received either ACT001 or parthenolide are not eligible.

Primary outcomes:
measure: Overall Survival (OS) for newly diagnosed DIPG
timeFrame: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
measure: Objective Response Rate (ORR) in Progressive/Refractory/Recurrent HGG after frontline RT
timeFrame: Date on treatment through 30 days following end of protocol treatment
Secondary outcomes:
measure: Overall Survival in Progressive/Refractory/Recurrent DIPG and H3K27-altered DIPG
timeFrame: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
Other outcomes:
Locations:
city: Washington
country: United States
facility: Children's National Medical Center
state: District of Columbia
city: Miami
country: United States
facility: Nicklaus Children's Hospital
state: Florida
city: Atlanta
country: United States
facility: Emory University/Children's Healthcare of Atlanta
state: Georgia
city: Ann Arbor
country: United States
facility: C.S. Mott Children's Hospital
state: Michigan
city: St. Louis
country: United States
facility: St. Louis Children's Hospital
state: Missouri
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital
state: Ohio
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
city: Philidelphia
country: United States
facility: Children's Hospital of Philidelphia
state: Pennsylvania
city: Houston
country: United States
facility: Texas Children's Hospital
state: Texas
city: Seattle
country: United States
facility: Seattle Children's Hospital
state: Washington
city: Randwick
country: Australia
facility: Sydney Children's Hospital
state: New South Wales
city: South Brisbane
country: Australia
facility: Queensland Children's Hospital
state: Queensland
city: Melbourne
country: Australia
facility: Royal Children's Hospital
state: Victoria
city: Perth
country: Australia
facility: Perth Children's Hospital
state: Western Australia
city: Toronto
country: Canada
facility: The Hospital for Sick Children (SickKids)
state: Ontario
city: Montréal
country: Canada
facility: Montreal Children's Hospital
state: Quebec
city: Heidelberg
country: Germany
facility: Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)
state: Baden-Württemberg
Study officials:
affiliation: Sydney Children's Hospitals Network
name: David S. Ziegler, MD, FRACP
role: STUDY_CHAIR
affiliation: Nationwide Children's Hospital
name: Sara Khan, MD, PhD, FRACP
role: STUDY_CHAIR
References: